Last updated: September 14, Showing trials for All Female Male. All ages Under 18 Over Olaparib In Metastatic Breast Cancer open to eligible people ages 18 years and up This research study is for patients with metastatic breast cancer.
This article has been cited by other articles in PMC. Introduction Immune checkpoint inhibitors ICIs have achieved impressive success in a subset of malignant tumors. Methods This cohort study was deemed exempt from institutional review board approval and informed consent by the University of Oklahoma Health Sciences Center ethics committee, as only deidentified human samples were used. Open in a separate window. Figure 1. Figure 2. References 1. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Cancer Discov. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. Lancet Oncol. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.
JAMA Oncol. January 24, Related Resources. Basser Young Leadership Council Info.
0コメント